Visualize the benefits. Experience the difference.



ClearVisc™

2.5% sodium hyaluronate

PROTECTION

- ClearVisc™ is specifically designed with a molecular weight and viscosity that optimizes endothelial cell protection.[1]
- ClearVisc™ features a proprietary formulation of sodium hyaluronate and sorbitol shown to inhibit free radicals.[2]

CLARITY

- ClearVisc™ helps to ensure excellent tissue visualization by minimizing the capture of bubbles and other material during the procedure.

VOLUME

- ClearVisc™ is supplied in a 1.0 ml syringe, which reduces the need to open a second pack mid-procedure.

FREE RADICALS IN CATARACT SURGERY / SORBITOL PROTECTION / PROCEDURAL CLARITY / PROVEN PERFORMANCE

BAUSCH+LOMB

ORDER NUMBER	DVISC10
SIZE	1.0mL
VISCOSITY, CP (AT 1S-1 SHEAR RATE, 25°C)	40,000
MOLECULAR WEIGHT (DALTONS)	<1.0 million
COMPOSITION	2.5% HA 4% Sorbitol
COHESION	Dispersive
OSMOLALITY (MOSM/KG)	330
CANNULA SIZE	27G

Set up your ClearVisc™ trial

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CLEARVISC™ OVD
ClearVisc™ is indicated for use as a surgical aid in ophthalmic anterior segment procedures including: Extraction of cataract; Implantation of an intraocular lens (IOL.)

PRECAUTIONS
Precautions normally considered during anterior segment procedures are recommended. Pre-existing glaucoma may place patients at risk for increases in intraocular pressure from the OVD during the early postoperative period.

WARNINGS
- Do not use if the sterile barrier has been breached. Sterility cannot be guaranteed, and the patient will be at increased risk for infection.
- An excess quantity of ClearVisc should not be used. Excess OVD can cause increased intraocular pressure.
- ClearVisc should be removed from the anterior chamber at the end of surgery to prevent or minimize postoperative intraocular pressure increases (spikes). OVD remaining in the eye can cause increased intraocular pressure.
- If the postoperative intraocular pressure increases above expected values, corrective therapy should be administered. Increased intraocular pressure may lead to inflammation or vision loss.
- Do not re-use the cannula. Even after cleaning and rinsing, resterilized cannula could release particulate matter as ClearVisc is injected. It is recommended that a single-use disposable cannula be used when administering ClearVisc. Reuse may cause eye inflammation.
- If any particulate matter is observed, it should be removed by irrigation and/or aspiration. Particulate matter left in the eye may cause increased IOP or light scattering /obstruction.
- Store at 2° to 8°C (36° to 46°F). Protect from freezing. The shelf life of ClearVisc is not guaranteed if it is not properly stored.

ADVERSE REACTIONS
Sodium hyaluronate is a natural component of tissues within the body and is generally well tolerated in human eyes. Transient postoperative inflammatory reactions and increases in intraocular pressure have been reported. Inflammation may result from increased intraocular pressure caused by use of the OVD. Intraocular inflammation, i.e., toxic anterior segment syndrome (TASS), has been attributed to OVDs. Furthermore, vision loss may be possible as a result of increased intraocular pressure and inflammation.

ATTENTION
Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc.

CAUTION
Federal (USA) law restricts this device to the sale by or on the order of a physician.

References: 1. ClearVisc Directions for Use 2. Data on file

FREE RADICALS IN CATARACT SURGERY / SORBITOL PROTECTION / PROCEDURAL CLARITY / PROVEN PERFORMANCE

BAUSCH+LOMB